Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Biophytis SA Sponsored ADR BPTSY

Healthcare  —  Biotechnology
0.25 0.00 0.00% as of 24 Sep
Market cap
$2.4M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Biophytis SA Sponsored ADR (BPTSY) Business Profile

Updated before January 2025

Company Overview

Biophytis SA Sponsored ADR (BPTSY) is a clinical-stage biotechnology company headquartered in Paris, France. Founded in 2006, the company is dedicated to developing therapeutics that target aging-related diseases and improve the quality of life for patients suffering from degenerative conditions. Biophytis operates with a mission to address unmet medical needs in the fields of neuromuscular diseases, respiratory diseases, and other age-related conditions. The company is led by a team of experienced professionals, including its CEO, Stanislas Veillet, who has a strong background in biotechnology and pharmaceutical development. Biophytis is listed on the NASDAQ under the ticker symbol BPTSY and has a global presence with operations in both Europe and the United States.

Core Business Segments

Biophytis focuses on the development of innovative therapeutics in the following key areas:

1. Neuromuscular Diseases

Biophytis is actively developing treatments for neuromuscular disorders, with a particular focus on sarcopenia, a condition characterized by the loss of muscle mass and strength due to aging. The company’s lead product candidate in this segment is Sarconeos (BIO101), which is currently in clinical trials. Sarconeos aims to improve muscle function and physical performance in patients suffering from sarcopenia.

2. Respiratory Diseases

Another major focus area for Biophytis is the treatment of respiratory diseases, particularly those exacerbated by aging. Sarconeos (BIO101) is also being investigated for its potential to treat severe respiratory complications associated with COVID-19. This dual application of Sarconeos highlights the company’s commitment to addressing critical health challenges.

3. Rare and Degenerative Diseases

Biophytis is exploring therapeutic solutions for rare and degenerative diseases, leveraging its expertise in biology and pharmacology. The company’s pipeline includes preclinical and early-stage programs targeting other age-related conditions.

Business Model

Biophytis operates as a research-driven biotechnology company, focusing on the discovery, development, and commercialization of novel therapeutics. The company’s business model revolves around:

  • Research and Development (R&D): Biophytis invests heavily in R&D to advance its pipeline of drug candidates. The company collaborates with academic institutions, research organizations, and industry partners to accelerate innovation.
  • Clinical Trials: Biophytis conducts rigorous clinical trials to ensure the safety and efficacy of its products. The company’s lead candidate, Sarconeos, is currently in Phase 2 and Phase 3 trials for various indications.
  • Partnerships and Licensing: To expand its reach and capabilities, Biophytis forms strategic partnerships with pharmaceutical companies and other stakeholders. Licensing agreements also play a key role in generating revenue.
  • Regulatory Approvals: The company works closely with regulatory authorities to obtain approvals for its drug candidates, paving the way for commercialization.

Revenue generation for Biophytis is primarily tied to successful drug development and commercialization, as well as licensing and partnership agreements.

Strategic Direction

Biophytis has outlined a clear strategic roadmap to achieve its long-term goals:

  • Advancing Clinical Programs: The company is focused on advancing Sarconeos through late-stage clinical trials and obtaining regulatory approvals for its use in treating sarcopenia and COVID-19-related respiratory complications.
  • Expanding the Pipeline: Biophytis aims to diversify its portfolio by developing new drug candidates targeting other age-related diseases and rare conditions.
  • Global Expansion: The company is working to strengthen its presence in key markets, including North America, Europe, and Asia, to maximize the impact of its therapies.
  • Sustainability Goals: Biophytis is committed to sustainable practices in its operations, including ethical research and minimizing its environmental footprint.
  • Innovation and Collaboration: The company continues to invest in cutting-edge technologies and foster collaborations with academic and industry partners to drive innovation.

Competitive Landscape

Biophytis operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its innovative therapies in various therapeutic areas, including aging-related diseases.
  • Sarepta Therapeutics: Focused on neuromuscular diseases, particularly Duchenne muscular dystrophy.
  • Amgen: A global leader in biotechnology with a strong portfolio of products targeting aging-related conditions.
  • Smaller Biotech Firms: Numerous smaller companies are also developing therapies for sarcopenia, respiratory diseases, and other age-related conditions.

Biophytis differentiates itself through its focus on aging-related diseases and its innovative approach to drug development.

Risk Factors

Like any biotechnology company, Biophytis faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its drug candidates could hinder commercialization efforts.
  • Clinical Trial Risks: Unsuccessful clinical trials or adverse safety findings could negatively affect the company’s prospects.
  • Market Dependence: Biophytis relies heavily on the success of its lead candidate, Sarconeos, which poses a concentration risk.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing could delay product development and commercialization.
  • Competitive Pressure: Intense competition in the biotechnology sector could limit market opportunities for Biophytis.

Recent Developments

Biophytis has made significant progress in recent years, including:

  • Advancements in Sarconeos Trials: The company has reported positive interim results from its Phase 2 and Phase 3 trials for Sarconeos in treating sarcopenia and COVID-19-related respiratory complications.
  • Partnerships: Biophytis has entered into strategic collaborations with academic institutions and industry partners to accelerate its R&D efforts.
  • COVID-19 Impact: The company has adapted its operations to address the challenges posed by the COVID-19 pandemic, including focusing on therapies for respiratory complications.
  • Regulatory Milestones: Biophytis has achieved key regulatory milestones, including obtaining orphan drug designation for certain indications.

Investment Considerations

Investors considering Biophytis should weigh the following factors:

Strengths:

  • Strong focus on aging-related diseases, a growing market segment.
  • Promising pipeline with Sarconeos as a lead candidate.
  • Experienced leadership team and strategic partnerships.
  • Commitment to innovation and sustainability.

Risks:

  • Dependence on the success of a single lead candidate.
  • High R&D costs and potential delays in clinical trials.
  • Regulatory and competitive challenges.
  • Market volatility in the biotechnology sector.

Conclusion

Biophytis SA Sponsored ADR (BPTSY) is a pioneering biotechnology company with a strong focus on developing therapeutics for aging-related diseases. With a promising pipeline, strategic partnerships, and a commitment to innovation, the company is well-positioned to address critical health challenges. However, investors should carefully consider the risks associated with clinical-stage biotechnology companies. As Biophytis advances its clinical programs and expands its global presence, it has the potential to make a significant impact in the field of aging-related therapeutics.